276 related articles for article (PubMed ID: 28235006)
1. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
Simon M; Mesmar F; Helguero L; Williams C
PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
[TBL] [Abstract][Full Text] [Related]
2. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
[TBL] [Abstract][Full Text] [Related]
3. [
Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
[TBL] [Abstract][Full Text] [Related]
4. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
6. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
Lee IH; Lee SJ; Kang B; Lee J; Jung JH; Park HY; Park JY; Park NJ; Kim EA; Kang J; Chae YS
Breast Cancer Res Treat; 2024 May; 205(1):181-191. PubMed ID: 38279017
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
8. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
[TBL] [Abstract][Full Text] [Related]
9. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
[TBL] [Abstract][Full Text] [Related]
11. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
13. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
14. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
Li G; Yang M; Zuo L; Wang MX
Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
[TBL] [Abstract][Full Text] [Related]
15. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
[TBL] [Abstract][Full Text] [Related]
17. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
[TBL] [Abstract][Full Text] [Related]
18. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
[TBL] [Abstract][Full Text] [Related]
20. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
